Proscia Inc.

Proscia is an enterprise digital pathology company dedicated to rewiring pathology for precision medicine. Its flagship Concentriq platform — rated #1 by customers in the 2026 Best in KLAS rankings in both Europe and the United States — serves diagnostic laboratories, academic medical centers, health systems, commercial labs, biopharma and biotech companies, and contract research organizations (CROs). More than 12,000 pathologists and scientists use the platform daily, and Proscia counts 16 of the top 20 pharma leaders among its customers.

Proscia's mission is to transform the way diseases like cancer are fought by unifying digital pathology workflows, artificial intelligence, and real-world data generation across the full continuum from biomarker discovery through clinical diagnosis. The company has raised $50 million to advance AI-driven pathology and deliver the future of precision medicine.

Core Products

• Concentriq LS (Life Sciences): Purpose-built for biopharma, biotech, and CRO teams, Concentriq LS supports the full R&D lifecycle from biomarker discovery to clinical trials. It helps life sciences leaders fast-track breakthroughs, eliminate siloed pathology data, accelerate analysis, enable smarter collaboration, and stay ready for the future of image-based discovery. Recent releases address bottlenecks such as manual annotations, inefficient image navigation, and disconnected AI tools.
• Concentriq AP (Anatomic Pathology): Designed for academic medical centers, health systems, and commercial labs, Concentriq AP provides advanced digitization and AI capabilities to enable fully digital laboratory operations. It is built to improve diagnostic quality, increase efficiency, and position labs for future growth.
• Concentriq AP-Dx: An FDA-cleared solution for primary diagnosis, Concentriq AP-Dx offers an intuitive experience for interpreting and managing cases. It supports both late-stage clinical trials and routine diagnostic workflows, enabling labs to modernize their diagnostic processes.
• Proscia Aperture: A precision medicine solution that delivers real-time, point-of-diagnosis patient insights. Aperture turns pathology data into actionable insight at the moment of diagnosis, accelerating drug development and generating real-world evidence to support market access strategies.

AI Portfolio

• Proscia offers a comprehensive AI portfolio spanning development tools and analysis applications for both scientists and pathologists.
• The portfolio enables teams to build and deploy AI solutions that accelerate therapy development and deliver precision diagnostics.
• AI capabilities are integrated across the R&D lifecycle alongside Concentriq and Proscia Aperture to help bring treatments to market faster and reach more patients worldwide.

Solutions by Segment

• Life Sciences: Supports discovery, development, and delivery of therapies by deploying Concentriq LS, Proscia Aperture, and AI tools across the R&D pipeline, helping organizations turn pathology data into a competitive advantage.
• Anatomic Pathology / Diagnostics: Enables diagnostic labs to accelerate their shift to 100% digital diagnosis, improving diagnostic quality, increasing operational efficiency, and supporting long-term growth. Notable customers include PathGroup, whose Chief Medical Officer cites going 100% digital to accelerate growth, improve pathologist experience, and open new data opportunities with leading pharmas and CROs.

Platform Strengths and Recognition

• Recognized as Best in KLAS in Europe and achieving the top score in the US for 2026, with particular recognition for proven diagnostic workflows and seamless interoperability.
• FDA-cleared for primary diagnosis through the Concentriq AP-Dx product.
• Trusted by major CROs and 16 of the top 20 global pharmaceutical companies.
• Used daily by more than 12,000 pathologists and scientists across diagnostic laboratories and life sciences organizations.
• Partners with leading academic medical centers such as Cleveland Clinic, which has leveraged the platform for digital pathology adoption and change management at scale.

Proscia continues to invest in advancing its platform, with ongoing product development focused on expanding AI capabilities, deepening interoperability, and supporting the broader shift toward precision medicine across both clinical and research settings.